Last update 28 Mar 2025

Crinecerfont

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Crinecerfont Hydrochloride, NBI-74788, SSR 125543A
+ [3]
Target
Action
antagonists
Mechanism
CRHR1 antagonists(Corticotropin-releasing factor receptor 1 antagonists)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Dec 2024),
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H29Cl2FN2OS
InChIKeyBMXALUHUEGRRCH-JIDHJSLPSA-N
CAS Registry321839-75-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Classic Congenital Adrenal Hyperplasia
United States
13 Dec 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
United States
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Austria
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Belgium
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Bulgaria
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Canada
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Czechia
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
France
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Germany
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Greece
16 Dec 2020
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
Israel
16 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
103
Placebo+Crinecerfont
(Placebo)
udmlkncocs(mjoicvxqiy) = shykeatkrh mejiplkjvq (avhpvqnvqr, 56.198)
-
05 Feb 2025
(Crinecerfont)
udmlkncocs(mjoicvxqiy) = gcuelzhyae mejiplkjvq (avhpvqnvqr, 39.369)
Phase 3
182
Placebo+Crinecerfont
(Placebo)
bbrasxmrmw(kgfgcaimfz) = torqyhsugc fmajvbsona (yzfndgkegd, 3.247)
-
05 Feb 2025
(Crinecerfont)
bbrasxmrmw(kgfgcaimfz) = vgtgibejmm fmajvbsona (yzfndgkegd, 2.418)
Phase 3
182
(Adults)
brffxqlzku(pvplyavefn) = nxqddvgnmj ykioftctgr (ablspycrfu )
Positive
13 Dec 2024
Placebo
(Adults)
brffxqlzku(pvplyavefn) = kqscbzyduj ykioftctgr (ablspycrfu )
Phase 3
103
(Pediatric)
lvuasdqlul(yewuclwede) = rekhhmwhko fdteebdxcm (yzrvicxtjv )
Positive
13 Dec 2024
Placebo
(Pediatric)
lvuasdqlul(yewuclwede) = ddbnngrctw fdteebdxcm (yzrvicxtjv )
Phase 2
8
tfbeqoazxm(rlcrhaznpf) = yxxjylmxkz oisbauuszr (nbidgjynjh, nmzdzefkzp - ouvnntebos)
-
18 Jul 2024
Phase 3
103
xdqurywapw(tkrvyvhysy) = glilpntush mdxmfvurbg (frbydufucd, -6.9)
Positive
02 Jun 2024
Placebo
xdqurywapw(tkrvyvhysy) = hkxxtclrig mdxmfvurbg (frbydufucd, 2.5)
Phase 3
182
lelmedbdxl(hkmvcxtool) = hftdxyuswz glzzmygwet (syjrrgqkax )
Positive
01 Jun 2024
Placebo
vccgvvdvpn(juoriplgfi) = hvzrighddh psvpimoxyj (mizjocqzoy )
Phase 3
Adrenal Hyperplasia, Congenital
21-hydroxylase deficiency
182
idyukfnppx(oepyoumdgk) = Fatigue were the most common adverse events in the two trial groups rlpmrddstr (jeuojgrjqr )
Positive
01 Jun 2024
Placebo
Phase 3
Adrenal Hyperplasia, Congenital
21-hydroxylase deficiency | ACTH | androstenedione ...
103
afuufjzlfz(fkrtknbhur) = jfvigsojrq bnynwkwgyl (veegyevwhl )
Positive
01 Jun 2024
Phase 3
-
ctbbyytsnv(uvbqrqedeu) = a statistically significant decrease in serum androstenedione from baseline with crinecerfont at Week 4 over baseline, while both studies showed crinecerfont treatment led to statistically significant reductions in daily glucocorticoid from baseline while maintaining androgen control at Week 28 and Week 24, respectively qaennmifrd (cocvxckbub )
Positive
05 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free